Empagliflozin Fails to Reduce Events After Acute MI : vimars

Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.

Related Keywords

New York , United States , Texas , Dallas , James Januzzi , Deepak Bhatt , Valentin Fuster , Carine Hamo , Michelle Albert , Javed Butler , Baylor Scott White Research Institute , American College Of Cardiology , Grossman School Of Medicine , Leonh Charney Division Of Cardiology , Department Of Medicine , American College , Scientific Sessions , New England Journal , Baylor Scott , White Research Institute , Mount Sinai Heart , Icahn School , Mount Sinai Health System , New York City , Lancet Diabetes , Myocardial Infarction , Heart Failure , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , T2dm , 2d , Chronic Renal Failure Kidney Ckd Disease , Renal Failure ,